Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of bivalent rLP2086 vaccine in healthy young adults
2009-014492-46Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in meningococcal disease comparing Bivalent rLP2086 vaccine with Placebo (2 arms). Primary endpoint: Immune response measured by hSBA against 10 secondary MenB test strains 1 month after dose 3. Started May 2011; status: completed.
02
Drugs
meningococcal group B recombinant lipoprotein 2086 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2009-014492-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014492-46.